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Abstract: Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line 
treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment 
of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in 
combination with different drugs or as single agent. Recently, pemetrexed has been approved 
in combination with cisplatin for the first-line treatment of patients with locally advanced or 
metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar 
to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is 
being evaluated in a phase III, double-blind, placebo-controlled study.
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Introduction
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death 
in both men and women in most of the Western world, with an estimated 900,000 
deaths per year worldwide.1 Occupational and environmental exposure to carcinogenic 
substances (eg, radon, asbestos, diesel exhaust fumes and metals) may increase the 
risk of developing lung cancer, but the risk is small compared with that associated 
with tobacco use.2 Most patients (approximately 80%) present with locally advanced 
stage III or metastatic stage IV NSCLC and are ineligible for curative surgery.3,4 The 
long-term prognosis for patients with NSCLC remains poor, the 5-year survival rate 
ranging from 8% to 15%.5
Some progress has been made in the treatment of advanced NSCLC during 
the past decade.6 Chemotherapy with cisplatin-based regimens was shown to 
prolong survival, relieve symptoms in most cases, and improve quality of life. 
The introduction of several new agents, including paclitaxel, gemcitabine, and 
vinorelbine, offered hope for a better outcome because overall survival improved 
with combination regimens that included these new agents compared with cisplatin 
alone.6 Phase III trials in NSCLC suggested that a plateau in clinical benefit has 
been reached with a median survival of 8 months. No specific regimen had superior 
therapeutic efficacy, as measured by overall survival.7 The addition of bevacizumab 
to platinum doublets has added 2 months of survival time compared with 
chemotherapy alone.8 Specifically an Italian phase III randomized trial comparing 
3 platinum doublets also showed no difference in efficacy endpoints between the 
different treatment arms, leading to the conclusion that chemotherapy in NSCLC 
had reached a therapeutic plateau.9
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Clearly additional new therapies with an innovative 
mode of action, improved efficacy and reduced toxicity are 
warranted.
Pemetrexed: a novel multitargeted 
antifolate
Pemetrexed (Alimta®; Eli Lilly and Company) is a novel 
multitargeted antifolate that inhibits 3 enzymes: thymidylate 
synthase, dihydrofolate reductase, and glycinamide ribo-
nucleotide formyl transferase.10 These enzymes are involved 
in the synthesis of nucleotides, ultimately hindering RNA and 
DNA synthesis. Investigational studies have demonstrated 
the cytotoxic activity of this agent in a broad range of tumor 
types including NSCLC. These studies also showed that 
combinations of pemetrexed with cisplatin, gemcitabine 
and taxanes produced additive or synergistic cytotoxicity.11 
Recent studies in humans also showed that vitamin supple-
mentation with B12 and folate reduced toxicity without 
nullifying the cytotoxic effects.12 Nowadays the standard 
vitamin supplementation consists of oral folic acid at 
350 to 1000 µg administered at least 5 continuous days prior 
to pemetrexed and continuing daily throughout therapy and 
vitamin B12 at 1000 µg administered intramuscularly prior 
to first dose of pemetrexed.13
Pemetrexed as first-line NSCLC 
treatment
Phase ii clinical trials
Pemetrexed as single agent
Multiple phase II trials involving pemetrexed have been 
completed in patients with NSCLC.
The single-agent activity of pemetrexed in the first-
line treatment of advanced NSCLC has been analyzed in 
2 open-label, phase II trials.
In 1999 Rusthoven14 enrolled 33 previously untreated 
patients with NSCLC to determine the response rate to single-
agent pemetrexed 500 mg/m2 every 21 days. The median 
patient age was 63 years. Among 30 patients evaluable for 
response, 7 had partial responses for response rate of 23%. 
Median survival was 9.2 months and 1-year survival rate 
was 25%. Grade 3–4 neutropenia was observed in 27% of 
patients, and 39% had grade 3–4 skin rash.
The other study was conducted in Australia and South 
Africa.15 Fifty-nine chemotherapy-naive patients with 
advanced NSCLC received 600 mg/m2 of pemetrexed. The 
response rate was 16%; median survival time was 7.2 months 
and 1-year survival rate was 32%. Grade 3–4 neutropenia was 
observed in 42% of patients and 31% had grade 3–4 skin rash. 
The study also revealed that 47 patients (80%) developed 
asymtomatic elevations in transaminase levels that returned 
to normal throughout the study.
More recently, another randomized phase II trial16 evalu-
ated single-agent pemetrexed 500 mg/m2 or sequential peme-
trexed 500 mg/m2 and gemcitabine 1200 mg/m2 in patients 
with NSCLC who were elderly (70 years) or younger than 
70 years and ineligible for platinum-based chemotherapy. 
Eighty-seven patients received treatment. Tumor response 
rates were 4.5% and 11.6% respectively for the peme-
trexed and pemetrexed/gemcitabine arms. Median overall 
survival time was 4.7 months for the pemetrexed arm and 
5.4 months for the pemetrexed/gemcitabine arms. Both 
hematological and non-hematological toxicities were mild. 
The study showed that single-agent pemetrexed and sequen-
tial pemetrexed/gemcitabine have moderate activity and are 
well tolerated as first-line treatment for advanced NSCLC in 
elderly patients or in patients unsuitable for platinum-based 
combination chemotherapy.
Pemetrexed platinum-based regimens
Clinical trials have also been conducted to evaluate front-line 
treatment with pemetrexed combined with a platinum agent.
Two phase II trials were conducted to evaluate the 
efficacy and safety of pemetrexed combined with cisplatin 
for advanced NSCLC.17,18 The designs of these two tri-
als were similar: pemetrexed 500 mg/m2 plus cisplatin 
75 mg/m2 on the first day of a 21-day cycle, without vitamin 
supplementation, but with dexamethasone prophylaxis. 
The first study was conducted in Germany and included 
36 chemotherapy-naive NSCLC patients. Median patient 
age was 58 years. The overall response rate was 39%, with 
a median survival rate of 10.9 months. Fifty-nine percent 
of patients had grade 3–4 granulocytopenia while 17% had 
grade 3–4 thrombocytopenia.
The National Cancer Institute of Canada study enrolled 
31 patients. Overall response rate was 45%, median overall 
survival was 8.9 months and 1-year survival rate was 49%. 
The regimen was well tolerated. Grade 3 or 4 granulocyto-
penia was seen in 7 and 4 patients, respectively; grade 3 or 4 
anemia was seen in 5 and 1 patients, reaspectively.
These results demonstrate the clinical activity of the 
cisplatin/pemetrexed combination for patients with advanced 
NSCLC and did not demonstrate significant increases in 
toxicity.
Pemetrexed has also been investigated in combination 
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80 patients were randomized to pemetrexed 500 mg/m2 
plus either carboplatin (area under the curve [AUC] 6) or 
oxaliplatin 120 mg/m2 on day 1 of a 3-week cycle, for up 
to 6 cycles.18 Low dose folic acid and vitamin B12 were 
provided. All efficacy outcomes measured were similar 
between the two combination doublets, and comparable to 
other combinations regimens, including cisplatin. However, 
the pemetrexed combination had a superior toxicity profile 
to the other platinum doublets.
In 2004 a single-institution, single-arm, phase II study 
demonstrated favorable activity with pemetrexed/carboplatin 
combination.19 The trial was conducted in 50 patients with 
adavanced NSCLC. Patients were administered carboplatin 
AUC 6 and pemetrexed 500 mg/m2 on day 1 every 21 days 
for a median of 6 cycles. The objective response rate was 
29%, median time to tumor progression 4.6 months, median 
overall survival 13.4 months and 1-year survival 52%.
In 2005 Zinner20 published an open study in which 
patients were treated with pemetrexed 500 mg/m2 and 
carboplatin (AUC 6) on day 1 every 3 weeks. Main grade 3–4 
toxicity was neutropenia (26%). Median time to progression 
was 5.4 months and overall survival 13.5 months, with a 
1-year survival of 56% (Table 1).
Pemetrexed platinum-free regimens
Monnerat21 reported results from a phase II trial of gemcitabine 
1250 mg/m2 on days 1 and 8, and pemetrexed 500 mg/m2 on 
day 8 every 21 days.The investigators administered routine 
vitamin supplementation. Overall response rate was 15.5%, 
and median overall survival was 10.1 months. The 1-year 
survival rate was 42.6%. Grade 3–4 neutropenia occurred 
in 61.7% of patients.
Another phase II clinical trial was conducted to evaluate 
various dosing regimens for a combination of pemetrexed 
and gemcitabine.22 Patients received pemetrexed followed 
by gemcitabine on day 1 and gemcitabine on day 8; or 
gemcitabine followed by pemetrexed on day 1 and gemcitabine 
on day 8; or gemcitabine on day 1 and pemetrexed followed 
by gemcitabine on day 8. The results demonstrated that the 
administration of pemetrexed on day 1 before gemcitabine 
on day 1 and 8 had the least toxicity, with efficacy similar to 
that of other administration schedules.
In 2006 Treat23 evaluated the combination of pemetrexed 
500 mg/m2 on day 1 and gemcitabine 1250 mg/m2 on day 1 
and 8 every 21 days. All patients received folic acid, vitamin 
B12 and steroid prophylaxis. A total of 53 patients were 
enrolled. Median time to disease progression was 3.3 months 
and median survival was 10.3 months. The toxicity was 
acceptable and similar to that of other NSCLC regimens.
In a recent meta-analysis24 of pemetrexed plus gemcitabine 
in first-line treatment of patients with advanced NSCLC, 
based on 4 trials, it was observed that the combination was 
efficacious and well tolerated. A phase I trial by Adjei25 estab-
lished the preferred sequence as 21-day cycles of gemcitabine 
1250 mg/m2 on days 1 and 8, and pemetrexed 500 mg/m2 
given 90 minutes after day 8 gemcitabine. Subsequent phase 
II studies in advanced NSCLC employed a 90-minute delay 
between gemcitabine and pemetrexed administration and 
demonstrated efficacy worthy of further study.26,27
Recently, a pharmacokinetic study conducted by Dy28 
found that the delay between gemcitabine and pemetrexed 
administration may be unnecessary.
West29 conducted a phase II clinical trial in which 
chemotherapy-naive patients with late-stage NSCLC 
received gemcitabine 1250 mg/m2 on days 1 and 8, with 
pemetrexed 500 mg/m2 immediately after day 8 gemcitabine 
every 21 days for 6 cycles, and folic acid, B12, and steroid 
prophylaxis.
The trial demonstrated that administering day 8 peme-
trexed immediately after gemcitabine does not appear to 
reduce therapeutic index.
In 2008 Dudek30 conducted a phase I/II trial: the phase 
I study included patients with advanced tumors, whereas 
the phase II study included patients with locally advanced 
or metastatic NSCLC. Gemcitabine was infused over 
30 minutes, followed by pemetrexed administered over 10 
Table 1 Pemetrexed in combination with platinum in the first-line setting for NSCLC (phase II)
MD Anderson trial20 European trial18
Concomitant drugs Pemetrexed + Carboplatin Pemetrexed + Carboplatin Pemetrexed + Oxaliplatin
No patients 50 39 41
ORR % 24.0 31.6 26.8
Survival (months) 13.5 10.5 10.5
PFS (months) 5.4 5.5 5.7
Abbreviations: ORR, overall response rate; PFS, progression free survival.Therapeutics and Clinical Risk Management 2009:5 784
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minutes on day 1 of a 14-day cycle. Treatment continued for 
12 cycles or until disease progression. All patients received 
folic acid, vitamin B12, and steroid prophylaxis. Dudek dem-
onstrated that twice-monthly gemcitabine and pemetrexed 
was well tolerated, with overall survival and clinical benefit 
indicating disease activity in NSCLC patients.
Pemetrexed has also been evaluated in combination 
with vinorelbine. In 2005 Clarke31 conducted a phase I/II 
study which enrolled 37 patients who received pemetrexed 
500 mg/m2 and vinorelbina 30 mg/m2. Median overall 
survival was 7.9 months, time to progression 4.4 months 
and median progression free survival 4.2 months. Main 
grade 3–4 toxicities reported were neutropenia (65%) and 
fatigue (8%).
Approved indications
Pemetrexed received in 2003 FDA approval for malignant 
pleural mesothelioma, based on a randomized, phase III, 
single-blind, multicenter trial that compared cisplatin alone 
versus cisplatin plus pemetrexed.32 The patients (n = 448) 
were randomized to receive pemetrexed 500 mg/m2 and 
cisplatin 75 mg/m2 or cisplatin alone at the same dose. The 
study demonstrated that pemetrexed significantly improves 
survival by 3 months when administered with cisplatin, with 
significant differences in overall response rate (41.3% vs 
16.7% in the pemetrexed/cisplatin arm and cisplatin alone 
arm, p  0.0001).
Pemetrexed was approved in 2004 as second-line therapy 
in patients with previously chemotherapy-treated advanced 
NSCLC based on a randomized, open-label, phase III 
trial.33
In this study 571 patients were randomly assigned to 
receive pemetrexed monotherapy (283 patients) or docetaxel 
monotherapy (288 patients). The trial showed that peme-
trexed and docetaxel had comparable activity and efficacy, 
with median survival times of approximately 8 months in 
both arms, but pemetrexed was associated with significantly 
less hematological toxicity and alopecia.
Based on this study, pemetrexed should be preferred over 
docetaxel as standard second-line NSCLC treatment.
Phase III clinical trials combined 
with platinum
At the XX ASCO meeting, Gronberg34 presented the data 
of a randomized study evaluating pemetrexed 500 mg/m2 
plus carboplatin AUC 5 day 1 or gemcitabine 1000 mg/m2 
day 1 and 8 plus carboplatin AUC 5 day 1. The investigators 
enrolled 437 patients. Of patients enrolled, 22% had poor 
performance status (PS = 2), and 18% were 75 years old, so 
the starting dose administered to elderly patients was reduced 
to 75% and the number of cycle permitted was 4. Median 
overall survival was 7.3 months and 7 months respectively 
in the pemetrexed/carboplatin arm and gemcitabine/carbo-
platin arms.
In 2008 Scagliotti35 reported results from a random-
ized, non-inferiority, phase III study. From July 2004 to 
December 2005, 1725 chemotherapy-naive patients with 
advanced NSCLC were assigned to receive either cisplatin 
75 mg/m2 on day 1 plus gemcitabine 1250 mg/m2 on days 
1 and 8 (cisplatin/gemicitabine arm) or cisplatin 75 mg/m2 
plus pemetrexed 500 mg/m2 on day 1 (ciplatin/pemetrexed 
arm), every 3 weeks for a maximum of 6 cycles. All patients 
received oral folic acid, vitamin B12 and dexamethasone pro-
phylaxis. The primary objective was to compare the overall 
survival between 2 regimens (Table 2).
Overall survival for patients in the cisplatin/pemetrexed 
group was non-inferior to the overall survival of patients in 
the cisplatin/gemcitabine group. Survival rates at 12 months 
were 43.5% and 41.9% for cisplatin/pemetrexed and 
cisplatin/gemcitabine respectively. Progression free survival 
and time to progressive disease were also non-inferior. For 
the cisplatin/pemetrexed doublet both hematologic and 
non-hematologic toxicities were significantly favorable.
Grade 3–4 neutropenia occurred in 15% of patients 
with pemetrexed and in 27% of patients with cisplatin/
gemcitabine. Anemia was observed in the 6% of patients 
in the cisplatin/pemetrexed arm and in the 10% of patients 
in the cisplatin/gemcitabine arm. Patients in the cisplatin/
gemcitabine arm required significantly more transfusions and 
supportive care interventions than did patients in the cisplatin/
pemetrexed arm.
Deaths attributed to study drug toxicity were low and 
were similar between arms (9 patients, 1%, for the cisplatin/
pemetrexed arm, and 6 patients, 0.7%, for the cisplatin/
gemcitabine arm).
Table 2 Histologic type of patients included in phase III CP vs CG 
in the first-line setting for NSCLC27
   CP 
N = 862
CG 
N = 863
Adenocarcinoma 436 (50.6%) 411 (47.6%)
Squamous cell carcinoma 244 (28.3%) 229 (26.5%)
Large cells 76 (8.8%) 77 (8.9%)
NSCLC, NOS 106 (12.3) 146 (16.9)
Abbreviations: CP, cisplatin/pemetrexed; CG, cisplatin/gemcitabine; NOS, no other 
specified.Therapeutics and Clinical Risk Management 2009:5 785
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Based on the results of this study, European regulatory 
approval of pemetrexed in combination with cisplatin has 
been granted for first-line treatment of patients with locally 
advanced or metastatic NSCLC other than predominantly 
squamous cell histology.
Differences in the efficacy between 
non-squamous and squamous patients
A prespecified analysis of the Scagliotti trials35 showed that 
patients with non-squamous tumors had significant improvement 
in overall survival. Patients in the cisplatin/pemetrexed arm 
with adenocarcinoma and large-cell carcinoma had signifi-
cantly better survival than patients in cisplatin/gemcitabine 
arm. Median survival in both arms was 10.28 months, with 
a hazard ratio of 0.93 and a non-inferiority p  0.0001. 
However, when comparing by histology type, significant 
differences were seen between the 2 arms in patients with 
adenocarcinoma and large cell carcinoma: those with adeno-
carcinoma who were randomized to cisplatin/pemetrexed 
had a median survival of 12.55 months vs 10.94 months for 
those in the cisplatin/gemcitabine arm. In patients with large 
cell carcinoma, patients randomized to cisplatin/pemetrexed 
had a median survival of 10.38 months vs 6.67 months for 
the cisplatin/gemcitabine arm.
In 2003 Sigmond36 demonstrated that patients with 
high levels of thymidylate synthase (TS) expression, such 
as those with squamous carcinoma, are less sensitive to 
pemetrexed.
In 2006 Ceppi37 reported that squamous cell and 
high-grade carcinoma are related to higher TS expression 
levels, which should be considered when treating patients 
with TS-inhibiting agent. This unfavorable effect on 
overall survival associated with squamous cell histology 
observed with pemetrexed was also noted in a retrospective 
analysis38 of the single-agent trial of pemetrexed versus 
docetaxel in patients with stage III/IV NSCLC after prior 
chemotherapy.31 Peterson showed that median overall 
survival and progression free survival in patients with 
non-squamous histology cancer treated with pemetrexed 
was higher than in those with squamous histology (overall 
survival 9.2 months vs 6.2 months, hazard ratio 0.48, 
p  0.001; progression free survival 3.4 vs 2.3, hazard ratio 
0.56, p  0.004).
A recent review from Hirsch39 considered the prognostic 
and predictive role of histology in advanced NSCLC.
The optimal duration of first-line treatment with 
platinum-based chemotherapy remains unclear. ASCO guide-
lines recommed that patients with stage IIIB and stage IV 
receive no more than 4 and 6 cycles40 because chemotherapy 
beyond 4 cycles was found to improve progression free 
survival but not overall survival, and to increase toxicity.41
Single-agent maintenance therapy could potentially 
provide a further increase in overall survival, slow disease 
progression, and improve quality of life with minimal side 
effects.
In 2008, Ciuleanu42 presented the results of a large, 
randomized phase III pivotal study in which pemetrexed 
demonstrated an advantage over best supportive care in a 
postinduction maintenance setting after administration of 
1 of 6 commonly prescribed induction regimens: carboplatin/
gemcitabine, cisplatin/gemcitabine, carboplatin/docetaxel, 
cisplatin/docetaxel, carboplatin/paclitaxel, or cisplatin/
paclitaxel. All patients received vitamin B12, folic acid and 
dexamethasone.
Patients treated with pemetrexed in postinduction 
maintenance therapy had superior progression free survival 
(4.3 vs 2.6 months; hazard ratio 0.502, 95% confidence 
interval 0.41–0.61, p  0.00001), especially in the 
non-squamous histology sub-group.
In the Ciuleanu study42 progression free survival was 
no different in the squamous cell patients treated with 
pemetrexed vs placebo, suggesting that, in patients with 
squamous cell carcinoma, the benefit with pemetrexed is 
lower. Patients with squamous cell carcinoma had a median 
progression free survival of 2.5 months with placebo and 
a median progression free survival of 2.48 months with 
pemetrexed.
By contrast, in patients with adenocarcinoma and large 
cell carcinoma, the benefit in progression free survival 
was significant. Patients with non-squamous carcinoma 
had a median progression free survival of 4.37 months 
with pemetrexed and a median progression free survival 
of 1.84 months with placebo. The number of large cell 
patients was small, but the difference was significant in the 
adenocarcinoma subgroup; in these patients, median progres-
sion free survival was 4.60 with pemetrexed and 2.66 months 
with placebo. There was also a significant benefit in overall 
survival in the subset of non-squamous patients; preliminary 
analysis showed a median overall survival of 14.4 months 
with pemetrexed and 9.4 months with placebo.
There were no significant toxicity differences between 
arms except for grade 3–4 anemia (pemetrexed 3.9%, placebo 
0.9%). Postinduction maintenance therapy with pemetrexed 
was well tolerated, and confirmed that pemetrexed was 
more efficacious in patients with non-squamous histology. 
Pemetrexed is a good candidate for maintenance therapy for Therapeutics and Clinical Risk Management 2009:5 786
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its efficacy, ease of administration and favorable toxicity 
profile.
Conclusions
Pemetrexed is active against advanced or metastatic NSCLC 
as both first- and second-line treatment.
It has the potential to play a key role in improving efficacy 
and toxicity, having demonstrated activity as a single or 
combination agent, other than predominantly squamous 
cell histology.
Postinduction maintenance therapy with pemetrexed 
is being evaluated in a phase III, double-blind, placebo 
controlled study.
The benefit with maintenance pemetrexed is a real change 
in the treatment paradigm, because in the past we had not 
seen any activity of an agent in the maintenance setting. 
Because pemetrexed can be administered over a prolonged 
period without cumulative toxicity, it may allow the disease 
to convert to a “chronic” state.
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